ESR1 and breast carcinoma: On the other hand, concerning HER2-positive breast cancer, the emergence of recurrence during or following adjuvant therapy may possibly be attributed to a spectrum of molecular alterations, including the activation of the PI3K/AKT pathway, PTEN loss, or heightened ER activation.